Purpose To this day, there is no cure for recurrent respiratory papillomatosis (RRP). Multiple
surgical procedures are performed to achieve symptom relief and prevention of airway …

Objectives/Hypothesis Systemic bevacizumab is a new adjuvant therapy for recurrent
respiratory papillomatosis (RRP) that has shown promising preliminary results in children …

Objective The clinical course of recurrent respiratory papillomatosis (RRP) varies from
spontaneous remission to severe airway obstruction with wide variability in recurrence …

Objectives/Hypothesis Recurrent respiratory papillomatosis (RRP) is a primarily benign
disease affecting the entire respiratory tract. Treatment is challenging and usually involves …

Objectives/Hypothesis Aggressive laryngeal, tracheal, and pulmonary papilloma is an
extremely challenging clinical problem without proven treatment options. A recent German …

Objectives/Hypothesis Recurrent respiratory papillomatosis (RRP) is a rare, potentially life‐
threatening, disease that impacts the voice, breathing, and quality of life of patients …

Objective: Unusual clinical course Background: Recurrent respiratory papillomatosis (RRP),
caused by human papillomavirus (HPV), is the most common benign neoplasm of the larynx …

Objectives/Hypothesis The purpose of this study is to develop consensus on key points that
would support the use of systemic bevacizumab for the treatment of recurrent respiratory …

Objectives Pulmonary papillomatosis is a rare but severe manifestation of recurrent
respiratory papillomatosis (RRP). Efficacy data of systemic bevacizumab for pulmonary RRP …

Recurrent respiratory papillomatosis (RRP) is a primary benign disease, which is
characterized by papillomatous growth in the respiratory tract. Malignant transformation …